Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903406 | 0.81 | CA1 (0.32) | — | |
| SCHEMBL4188554 | 0.81 | USP2 (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL16898660 | 0.76 | DUT (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL31171203 | 0.76 | DUT (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12013275 | 0.76 | DUT (0.40) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12501691 | 0.71 | — | — | |
| SCHEMBL10949282 | 0.70 | KDM4E (0.58) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10982965 | 0.70 | KDM4E (0.52) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL10433434 | 0.70 | — | — | |
| SCHEMBL26926934 | 0.70 | KDM4E (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938297-B2 | Process for the synthesis of everolimus and intermediates thereof | Cipia Limited (IN) | 2018-04-10 | — | — | US | disclosed |
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | CIPLA LIMITED (IN) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217988-A1 | Process for the Synthesis of Everolimus and Intermediates Thereof | MTOR, RICTOR, RPTOR | KDM4E 975/4885USP2 4476/4885ALDH1A1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.